Edgewise Therapeutics (EWTX) Stock
Oral drug developer for rare muscle disorders. Here's the price, business snapshot, and what's worth knowing about Edgewise Therapeutics in October 2026.
Edgewise Therapeutics (EWTX) is a clinical‑stage biopharmaceutical company developing oral small‑molecule therapies aimed at improving muscle function in neuromuscular and rare muscle disorders. With a market capitalisation of around $1.63bn, the business is largely valued on the progress of its pipeline and clinical data rather than current revenues. Investors should note the typical biotech risk profile: trial results, regulatory decisions and funding needs can drive significant share price movement. Edgewise's prospects depend on scientific proof of concept, safety outcomes and the company’s ability to fund development through pivotal studies. This summary is for educational purposes only and does not constitute personal investment advice. Consider suitability, diversification and your own risk tolerance before considering exposure to clinical‑stage biotechnology companies, as values can rise or fall and past performance is not a reliable indicator of future results.
Edgewise Therapeutics (EWTX) Stock Forecast
Analyst price target, next 12 months
$48.67
+23.8% vs today's $39.31
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Edgewise Therapeutics have a consensus 12-month target of $48.67, above the current price of $39.31.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edgewise Therapeutics' stock with a target price of $48.67, indicating growth potential.
Financial Health
Edgewise Therapeutics is doing well with strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EWTX
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline growth potential
Edgewise’s valuation is closely tied to clinical data; positive trial readouts could change outlook, though biotech results are uncertain and can disappoint.
Rare disease focus
Targeting rare and genetically defined muscle disorders can offer clearer regulatory paths and distinct patient needs, yet market size and reimbursement remain considerations.
Upcoming clinical catalysts
Near‑term study readouts and regulatory interactions may act as catalysts, while financing and safety outcomes are additional variables to watch.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
